Literature DB >> 431082

Immunotherapeutic effect of tumor necrosis after cryosurgery, electrocoagulation, and ligation.

H B Neel, R E Ritts.   

Abstract

Tumor necrosis in situ by cryosurgery, electrocoagulation, or ligation generally induces or augments some increase in tumor-specific transplantation immunity (TSTI) as compared with excision. Excision of the tumor 24 hours after it has been rendered ischemic by either ligation or cryosurgery seems to produce TSTI that is significantly greater than that after excision of viable tumor without prior ligation or cryosurgery; the degree of this immunity is similar to that seen after the tumor is left in situ indefinitely after treatment. These data suggest that most of the immunization following tumor necrosis in situ occurs within 24 hours of treatment. The experimental findings support the clinical reports of putative immunologic potentiation after tumor necrosis in situ.

Entities:  

Mesh:

Year:  1979        PMID: 431082     DOI: 10.1002/jso.2930110109

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  4 in total

Review 1.  Experimental cryosurgery investigations in vivo.

Authors:  A A Gage; J M Baust; J G Baust
Journal:  Cryobiology       Date:  2009-10-13       Impact factor: 2.487

2.  Magnetic resonance-guided percutaneous cryosurgery of breast carcinoma: technique and early clinical results.

Authors:  Jacques Morin; Amidou Traoré; Guy Dionne; Marcel Dumont; Bertrand Fouquette; Marie Dufour; Sonia Cloutier; Christian Moisan
Journal:  Can J Surg       Date:  2004-10       Impact factor: 2.089

3.  Tumor-specific immunity induced by cryoablation in a murine renal cell carcinoma model.

Authors:  Hyung Keun Kim; Jong Hyun Pyun; Seok Cho; Sung Gu Kang; Jeong Gu Lee; Je Jong Kim; Jun Cheon; Hong Seok Park; Seok Ho Kang
Journal:  Korean J Urol       Date:  2014-11-28

4.  Tumour devascularisation as a potential immunotherapeutic strategy.

Authors:  Tomas Buchler; Pavel Vasek; Radek Spisek; Pavel Skrobanek; Vaclav Horejsi
Journal:  Oncoimmunology       Date:  2018-10-11       Impact factor: 8.110

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.